{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:17:35Z","timestamp":1778735855107,"version":"3.51.4"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1005924","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000}}],"reference-count":82,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1005924","type":"journal-article","created":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T14:12:49Z","timestamp":1514902369000},"page":"e1005924","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":38,"title":["Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients"],"prefix":"10.1371","volume":"14","author":[{"given":"Shayna","family":"Stein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Haeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Vivanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4869-8842","authenticated-orcid":true,"given":"Franziska","family":"Michor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant Gliomas in Adults","volume":"359","author":"PY Wen","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"R Stupp","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"7436","key":"ref3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature11814","article-title":"Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance","volume":"494","author":"M Das Thakur","year":"2013","journal-title":"Nature"},{"issue":"19","key":"ref4","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"NP Shah","year":"2008","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1586\/14737140.7.9.1183","article-title":"Lapatinib in the treatment of breast cancer","volume":"7","author":"GM Higa","year":"2007","journal-title":"Expert Review of Anticancer Therapy"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IGC.0b013e31826d1438","article-title":"Expected Benefits of Topotecan Combined With Lapatinib in Recurrent Ovarian Cancer According to Biological Profile","author":"S Lheureux","year":"2012","journal-title":"International Journal of Gynecological Cancer"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ygyno.2011.10.022","article-title":"A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study","volume":"124","author":"AA Garcia","year":"2012","journal-title":"Gynecologic oncology"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ygyno.2012.07.127","article-title":"Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer","volume":"127","author":"KK Leslie","year":"2012","journal-title":"Gynecologic oncology"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1158\/1078-0432.CCR-11-2825","article-title":"A phase II study of lapatinib in recurrent\/metastatic squamous cell carcinoma of the head and neck","volume":"18","author":"JA de Souza","year":"2012","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/bjc.2011.237","article-title":"Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck","volume":"105","author":"JM Del Campo","year":"2011","journal-title":"British journal of cancer"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/COC.0b013e3181beac33","article-title":"A Multicenter Phase Ii Clinical Trial of Lapatinib (gw572016) in Hormonally Untreated Advanced Prostate Cancer","volume":"33","author":"SS Sridhar","year":"2010","journal-title":"American Journal of Clinical Oncology"},{"issue":"18","key":"ref12","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-09-0465","article-title":"A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas","volume":"15","author":"T Bekaii-Saab","year":"2009","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-009-0927-7","article-title":"A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer","volume":"64","author":"RK Ramanathan","year":"2009","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"14","key":"ref14","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1200\/JCO.2007.14.5029","article-title":"Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial","volume":"26","author":"A Ravaud","year":"2008","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/1078-0432.CCR-12-1707","article-title":"A phase I\/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma","volume":"19","author":"DA Reardon","year":"2013","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00280-009-1041-6","article-title":"A phase I\/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation","volume":"65","author":"B Thiessen","year":"2010","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"17","key":"ref17","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1158\/1078-0432.CCR-09-0522","article-title":"A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies","volume":"15","author":"AJ Chien","year":"2009","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00228-016-2030-4","article-title":"Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment","volume":"72","author":"AHM de Vries Schultink","year":"2016","journal-title":"European journal of clinical pharmacology"},{"issue":"12","key":"ref19","first-page":"e85","article-title":"PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST","volume":"2","author":"EK Hansson","year":"2013","journal-title":"CPT: pharmacometrics & systems pharmacology"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10928-010-9164-2","article-title":"A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080","volume":"37","author":"RJ Keizer","year":"2010","journal-title":"Journal of pharmacokinetics and pharmacodynamics"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1208\/s12248-015-9815-8","article-title":"A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients","volume":"17","author":"AA Suleiman","year":"2015","journal-title":"The AAPS Journal"},{"issue":"1","key":"ref22","first-page":"e00016","article-title":"Developing Exposure\/Response Models for Anticancer Drug Treatment: Special Considerations","volume":"4","author":"DR Mould","year":"2015","journal-title":"CPT: pharmacometrics & systems pharmacology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1124\/dmd.112.049650","article-title":"Pharmacokinetic and Pharmacodynamic Modeling of Hedgehog Inhibitor TAK-441 for the Inhibition of Gli1 messenger RNA Expression and Antitumor Efficacy in Xenografted Tumor Model Mice","volume":"41","author":"A Kogame","year":"2013","journal-title":"DRUG METABOLISM AND DISPOSITION Drug Metab Dispos"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2007.10.008","article-title":"Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-<italic>\u03b2<\/italic> kinase antagonist, in mice","volume":"44","author":"L Bueno","year":"2008","journal-title":"European Journal of Cancer"},{"issue":"7","key":"ref25","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1124\/dmd.107.019711","article-title":"Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models","volume":"36","author":"S Yamazaki","year":"2008","journal-title":"Drug Metabolism and Disposition"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1124\/jpet.111.188870","article-title":"Pharmacokinetic\/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models","volume":"340","author":"S Yamazaki","year":"2012","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1124\/jpet.108.148189","article-title":"Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated","volume":"329","author":"H Wong","year":"2009","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"issue":"12","key":"ref28","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","article-title":"Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer","volume":"13","author":"C Grommes","year":"2011","journal-title":"Neuro-oncology"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1051\/mmnp\/20105304","article-title":"Modeling the Cancer Stem Cell Hypothesis","volume":"5","author":"C Calmelet","year":"2010","journal-title":"Math Model Nat Phenom"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"mdw556","DOI":"10.1093\/annonc\/mdw556","article-title":"Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with <italic>EGFR<\/italic> -mutant lung cancers","volume":"28","author":"HA Yu","year":"2016","journal-title":"Annals of Oncology"},{"issue":"90","key":"ref31","doi-asserted-by":"crossref","first-page":"90ra59","DOI":"10.1126\/scitranslmed.3002356","article-title":"Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling","volume":"3","author":"J Chmielecki","year":"2011","journal-title":"Science translational medicine"},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1158\/2159-8290.CD-11-0284","article-title":"Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors","volume":"2","author":"I Vivanco","year":"2012","journal-title":"Cancer discovery"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/sj.bjc.6604125","article-title":"A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle","volume":"98","author":"KR Swanson","year":"2008","journal-title":"British Journal of Cancer"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"e2434","DOI":"10.1038\/cddis.2016.318","article-title":"Glioblastoma, hypoxia and autophagy: a survival-prone \u2018m\u00e9nage-\u00e0-trois\u2019","volume":"7","author":"S Jawhari","year":"2016","journal-title":"Cell Death and Disease"},{"key":"ref35","article-title":"Why one-size-fits-all vaso- modulatory interventions fail to control glioma invasion: in silico insights. Nature Publishing Group","author":"JCL Alfonso","year":"2016","journal-title":"Why one-size-fits-all vaso- modulatory interventions fail to control glioma invasion: in silico insights. Nature Publishing Group"},{"issue":"6","key":"ref36","first-page":"2","article-title":"Journal of Biological Dynamics Glioblastoma brain tumours: estimating the time from brain tumour initiation and resolution of a patient survival anomaly after similar treatment protocols Glioblastoma brain tumours: estimating the time from brain tumour in","volume":"6","author":"JD Murray","year":"2012","journal-title":"Journal of Biological Dynamics"},{"issue":"21","key":"ref37","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1158\/1078-0432.CCR-09-0369","article-title":"A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies","volume":"15","author":"HA Burris","year":"2009","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"18","key":"ref38","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.2146\/ajhp070646","article-title":"Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer","volume":"65","author":"B Paul","year":"2008","journal-title":"American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists"},{"issue":"9","key":"ref39","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/nm0901-1010","article-title":"Glutamate release promotes growth of malignant gliomas","volume":"7","author":"T Takano","year":"2001","journal-title":"Nature Medicine"},{"issue":"3","key":"ref40","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The Microenvironmental Landscape of Brain Tumors","volume":"31","author":"DF Quail","year":"2017","journal-title":"Cancer cell"},{"issue":"5","key":"ref41","first-page":"466","article-title":"Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib","volume":"12","author":"ER Gerstner","year":"2010","journal-title":"Neuro-oncology"},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"24912","DOI":"10.1038\/srep24912","article-title":"Strategies of Mesenchymal Invasion of Patient-derived Brain Tumors: Microenvironmental Adaptation","volume":"6","author":"J Cha","year":"2016","journal-title":"Scientific Reports"},{"issue":"16","key":"ref43","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/glia.20895","article-title":"PDGF stimulates the massive expansion of glial progenitors in the neonatal forebrain","volume":"57","author":"MC Assanah","year":"2009","journal-title":"Glia"},{"issue":"8","key":"ref44","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/glia.21136","article-title":"The brain tumor microenvironment","volume":"59","author":"NA Charles","year":"2011","journal-title":"Glia"},{"issue":"9","key":"ref45","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/01.jnen.0000178445.33972.a9","article-title":"Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2","volume":"64","author":"DS Markovic","year":"2005","journal-title":"Journal of neuropathology and experimental neurology"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2184.1995.tb00036.x","article-title":"A mathematical model of glioma growth: the effect of chemotherapy on spatio-temporal growth","volume":"28","author":"P Tracqui","year":"1995","journal-title":"Cell Proliferation"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fonc.2013.00062","article-title":"From Patient-Specific Mathematical Neuro-Oncology to Precision Medicine","volume":"3","author":"AL Baldock","year":"2013","journal-title":"Frontiers in Oncology"},{"key":"ref48","first-page":"1","article-title":"Simulating PDGF-Driven Glioma Growth and Invasion in an Anatomically Accurate Brain Domain","author":"SC Massey","year":"2017","journal-title":"Bulletin of Mathematical Biology"},{"issue":"5","key":"ref49","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s11538-015-0067-7","article-title":"Patient-specific mathematical neuro-oncology: using a simple proliferation and invasion tumor model to inform clinical practice","volume":"77","author":"PR Jackson","year":"2015","journal-title":"Bulletin of mathematical biology"},{"issue":"3","key":"ref50","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1227\/00006123-198803000-00003","article-title":"Survival after stereotactic biopsy of malignant gliomas","volume":"22","author":"RJ Coffey","year":"1988","journal-title":"Neurosurgery"},{"issue":"4","key":"ref51","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","volume":"168","author":"N McGranahan","year":"2017","journal-title":"Cell"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"7979","DOI":"10.1038\/srep07979","article-title":"The Evidence of Glioblastoma Heterogeneity","volume":"5","author":"A Soeda","year":"2015","journal-title":"Scientific Reports"},{"issue":"7467","key":"ref53","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature12625","article-title":"The causes and consequences of genetic heterogeneity in cancer evolution","volume":"501","author":"RA Burrell","year":"2013","journal-title":"Nature"},{"issue":"1","key":"ref54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-017-0600-4","article-title":"Intra-tumor heterogeneity from a cancer stem cell perspective","volume":"16","author":"PR Prasetyanti","year":"2017","journal-title":"Molecular Cancer"},{"issue":"19","key":"ref55","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1158\/0008-5472.CAN-12-2217","article-title":"Intratumor heterogeneity: evolution through space and time","volume":"72","author":"C Swanton","year":"2012","journal-title":"Cancer research"},{"issue":"11","key":"ref56","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1158\/1940-6207.CAPR-10-0234","article-title":"The origins and implications of intratumor heterogeneity","volume":"3","author":"F Michor","year":"2010","journal-title":"Cancer prevention research (Philadelphia, Pa)"},{"issue":"11","key":"ref57","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1134\/S0006297913110011","article-title":"Intratumor heterogeneity: Nature and biological significance","volume":"78","author":"TS Gerashchenko","year":"2013","journal-title":"Biochemistry (Moscow)"},{"issue":"8","key":"ref58","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1158\/1940-6207.CAPR-16-0096","article-title":"Understanding Intratumoral Heterogeneity: Lessons from the Analysis of At-Risk Tissue and Premalignant Lesions in the Colon","volume":"9","author":"CK Sievers","year":"2016","journal-title":"Cancer prevention research (Philadelphia, Pa)"},{"issue":"10","key":"ref59","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing","volume":"366","author":"M Gerlinger","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"ref60","article-title":"Tumour Cell Heterogeneity","volume":"5","author":"L Gay","year":"2016","journal-title":"F1000Research"},{"issue":"3","key":"ref61","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/bjc.2012.581","article-title":"Cancer heterogeneity: implications for targeted therapeutics","volume":"108","author":"R Fisher","year":"2013","journal-title":"British journal of cancer"},{"issue":"2","key":"ref62","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.1986.4.2.244","article-title":"Tumor heterogeneity and drug resistance","volume":"4","author":"DL Dexter","year":"1986","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"7467","key":"ref63","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/501327a","article-title":"Tumour heterogeneity","volume":"501","author":"B Marte","year":"2013","journal-title":"Nature"},{"issue":"1","key":"ref64","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-cancerbio-042516-011348","article-title":"Deciphering Genetic Intratumor Heterogeneity and Its Impact on Cancer Evolution","volume":"1","author":"R Rosenthal","year":"2017","journal-title":"Annual Review of Cancer Biology"},{"issue":"5","key":"ref65","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrc3261","article-title":"Intra-tumour heterogeneity: a looking glass for cancer?","volume":"12","author":"A Marusyk","year":"2012","journal-title":"Nature Reviews Cancer"},{"issue":"2","key":"ref66","article-title":"Tumor Heterogeneity, Single-Cell Sequencing, and Drug Resistance","volume":"9","author":"F Schmidt","year":"2016","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"1","key":"ref67","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/PPO.0b013e318244d8ae","article-title":"Novel delivery strategies for glioblastoma","volume":"18","author":"J Zhou","year":"2012","journal-title":"Cancer journal (Sudbury, Mass)"},{"issue":"4","key":"ref68","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3171\/jns.1995.82.4.0615","article-title":"Assessment of brain tumor cell motility <italic>in vivo<\/italic> and <italic>in vitro<\/italic>","volume":"82","author":"MR Chicoine","year":"1995","journal-title":"Journal of Neurosurgery"},{"issue":"1","key":"ref69","first-page":"62","article-title":"The limited value of cytoreductive surgery in elderly patients with malignant gliomas","volume":"34","author":"PJ Kelly","year":"1994","journal-title":"Neurosurgery"},{"issue":"4","key":"ref70","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3892\/ol.2016.4952","article-title":"Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches","volume":"12","author":"WJ Huang","year":"2016","journal-title":"Oncology letters"},{"issue":"1","key":"ref71","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2015.01.010","article-title":"Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1<italic>\u03b1<\/italic>-ZEB1 axis","volume":"359","author":"JV Joseph","year":"2015","journal-title":"Cancer letters"},{"issue":"12","key":"ref72","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1093\/neuonc\/nou147","article-title":"Targeting adaptive glioblastoma: an overview of proliferation and invasion","volume":"16","author":"Q Xie","year":"2014","journal-title":"Neuro-oncology"},{"issue":"136","key":"ref73","doi-asserted-by":"crossref","first-page":"20170490","DOI":"10.1098\/rsif.2017.0490","article-title":"The biology and mathematical modelling of glioma invasion: a review","volume":"14","author":"JCL Alfonso","year":"2017","journal-title":"Journal of the Royal Society, Interface"},{"issue":"2","key":"ref74","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/(SICI)1097-0215(19960717)67:2<275::AID-IJC20>3.0.CO;2-9","article-title":"Dichotomy of astrocytoma migration and proliferation","volume":"67","author":"A Giese","year":"1996","journal-title":"International Journal of Cancer"},{"issue":"1","key":"ref75","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/imammb\/dqq011","article-title":"\u2018Go or Grow\u2019: the key to the emergence of invasion in tumour progression?","volume":"29","author":"H Hatzikirou","year":"2012","journal-title":"Mathematical Medicine and Biology"},{"issue":"6","key":"ref76","doi-asserted-by":"crossref","first-page":"e1002556","DOI":"10.1371\/journal.pcbi.1002556","article-title":"The Impact of Phenotypic Switching on Glioblastoma Growth and Invasion","volume":"8","author":"P Gerlee","year":"2012","journal-title":"PLoS Computational Biology"},{"issue":"1","key":"ref77","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2004.08.110","article-title":"Phase II trial of gefitinib in recurrent glioblastoma","volume":"22","author":"JN Rich","year":"2004","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"1","key":"ref78","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1215\/S1522851705000451","article-title":"Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma","volume":"8","author":"MD Prados","year":"2006","journal-title":"Neuro-oncology"},{"issue":"34","key":"ref79","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1200\/JCO.2008.18.0612","article-title":"Phase I\/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177","volume":"26","author":"PD Brown","year":"2008","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"36","key":"ref80","doi-asserted-by":"crossref","first-page":"9359","DOI":"10.1200\/JCO.2005.03.2185","article-title":"Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme","volume":"23","author":"DA Reardon","year":"2005","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"16","key":"ref81","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1158\/1078-0432.CCR-06-0773","article-title":"Phase I\/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08","volume":"12","author":"PY Wen","year":"2006","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"28","key":"ref82","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1200\/JCO.2008.16.9235","article-title":"Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study","volume":"26","author":"E Raymond","year":"2008","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1005924","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1005924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T17:17:02Z","timestamp":1540315022000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1005924"}},"subtitle":[],"editor":[{"given":"Alexander R.A.","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,1,2]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1005924","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pcbi.1005924","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,2]]}}}